Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
- 1 December 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 31 (6), 683-687
- https://doi.org/10.1097/ftd.0b013e3181c05a14
Abstract
: A quantitative liquid chromatography (LC)-mass spectrometry (MS)/MS method in human plasma was developed and validated for the tyrosine kinase inhibitors erlotinib, gefitinib, and imatinib in human plasma. Pre-treatment of the samples was achieved by using liquid-liquid extraction using D-8 imatinib as internal standard. Separation was performed on a Waters Alliance 2795 LC system using an XBridge RP18 column. The mass spectrometer Micromass was equipped with an electro spray ionization probe, operating in the positive mode. The calibration curves in plasma were linear for erlotinib, gefitinib, and imatinib over the concentration range of 5 to 3,000; 5 to 3,000, and 5 to 5,000 ng/mL, respectively. The intraday and interday accuracy ranged from 90% to 110% and the intraday and interday precision of the method was within 5%. The reported method provided the necessary linearity, precision, and accuracy to determine tyrosine kinase inhibitors in clinical research and for therapeutic drug monitoring.Keywords
This publication has 14 references indexed in Scilit:
- Rhabdomyolysis Resulting from Pharmacologic Interaction Between Erlotinib and SimvastatinClinical Lung Cancer, 2008
- Significant drug interaction: Phenytoin toxicity due to erlotinibLung Cancer, 2007
- Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2005
- Drug Interaction Between Gefitinib and WarfarinJapanese Journal of Clinical Oncology, 2005
- Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2005
- Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjectsCancer Chemotherapy and Pharmacology, 2004
- Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer TreatmentJNCI Journal of the National Cancer Institute, 2003
- Imatinib Mesylate — A New Oral Targeted TherapyThe New England Journal of Medicine, 2002
- Angiogenesis in Lymphoproliferative DisordersActa Haematologica, 2001
- Issues in evaluation of bioanalytical method selectivity and drug stabilityJournal of Pharmaceutical and Biomedical Analysis, 1995